InSite Vision, Inc.
About InSite Vision

Building Leadership
Preserving and improving vision worldwide

InSite Vision, a SUN PHARMA company is committed to advancing new and superior ophthalmologic products for unmet eye care needs.  Our goal is to develop and facilitate market entry for novel products worldwide that preserve and improve vision. To date, we have accomplished this mission with the approval of three DuraSite-based ophthalmologic products:

Our first marketed product, AzaSite® (azithromycin ophthalmic solution) 1%, is approved by the United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis (pink eye). AzaSite is formulated with our DuraSite® technology, which extends the residence time of the antibiotic azithromycin on the eye for several hours. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals and is now marketed by Akorn, Inc. (NASDAQ:AKRX).

Our second marketed product, Besivance® (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a broad spectrum ocular antibiotic approved by the FDA in May 2009 to treat bacterial conjunctivitis (pink eye). An advantage of Besivance is a faster rate of resolution of the infection that may reduce the duration of the illness and reduce the chances of infecting others. Besivance was developed by Bausch & Lomb and launched in the United States in the second half of 2009.

Our third approved product, BromSite(ISV-303) (bromfenac ophthalmic solution) 0.075%, is a Durasite formulation containing a low dose of bromfenac non-steroidal anti-inflammatory drug. BromSite was approved by the FDA in April 2016 for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.

DexaSite(ISV-305), a DuraSite formulation of 0.1% dexamethasone, is in Phase 3 development for the treatment of ocular surface inflammation (e.g.,blepharitis), and for the treatment of ocular pain and inflammation in cataract surgery.